--- title: "Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com" type: "News" locale: "en" url: "https://longbridge.com/en/news/233573036.md" description: "StockNews.com has initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI), assigning a \"hold\" rating. Other analysts have also provided ratings, with Piper Sandler maintaining a \"neutral\" rating and a target price of $132.00. The stock has an average rating of \"hold\" and a target price of $106.08. Intra-Cellular Therapies reported a quarterly loss of ($0.16) EPS, missing estimates, and had revenue of $199.22 million. Institutional investors own 92.33% of the company, which focuses on developing drugs for neuropsychiatric disorders." datetime: "2025-03-28T06:15:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/233573036.md) - [en](https://longbridge.com/en/news/233573036.md) - [zh-HK](https://longbridge.com/zh-HK/news/233573036.md) --- # Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com Equities researchers at StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a research note issued on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock. - MarketBeat Week in Review – 01/13 - 01/17 Several other analysts also recently commented on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $106.08. **Get Our Latest Stock Analysis on ITCI** ## Intra-Cellular Therapies Trading Up 0.0 % - Is Johnson & Johnson Stock Set to Reward Long-Term Holders? Shares of NASDAQ ITCI opened at $131.75 on Friday. The company has a market capitalization of $14.01 billion, a P/E ratio of -151.44 and a beta of 0.69. Intra-Cellular Therapies has a 12 month low of $64.09 and a 12 month high of $131.79. The stock has a 50 day moving average of $129.00 and a 200-day moving average of $99.05. Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year. ## Institutional Investors Weigh In On Intra-Cellular Therapies - Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Several institutional investors and hedge funds have recently bought and sold shares of ITCI. Cerity Partners LLC raised its position in shares of Intra-Cellular Therapies by 62.9% in the 3rd quarter. Cerity Partners LLC now owns 44,107 shares of the biopharmaceutical company's stock valued at $3,227,000 after buying an additional 17,027 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Intra-Cellular Therapies by 1.3% in the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company's stock valued at $1,614,000 after acquiring an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intra-Cellular Therapies by 13.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company's stock worth $1,648,000 after purchasing an additional 2,622 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Intra-Cellular Therapies by 3.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company's stock worth $23,649,000 after purchasing an additional 11,104 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in Intra-Cellular Therapies during the third quarter worth $2,195,000. Institutional investors own 92.33% of the company's stock. ## About Intra-Cellular Therapies (Get Free Report) Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. ## Further Reading - Five stocks we like better than Intra-Cellular Therapies - What is a SEC Filing? - Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell - Market Cap Calculator: How to Calculate Market Cap - Top 3 Beverage Stocks Pouring Out Profits - Investing in Construction Stocks - CarMax and Carvana: Steering the Used Car Market _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Intra-Cellular Therapies Right Now? Before you consider Intra-Cellular Therapies, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list. While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ITCI.US](https://longbridge.com/en/quote/ITCI.US.md) ## Related News & Research - [OS Therapies wins FDA Type C meeting to review 2.5-year survival data for OST-HER2 Phase 2b osteosarcoma trial](https://longbridge.com/en/news/295800970.md) - [The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech | NTHI Stock News](https://longbridge.com/en/news/295833253.md) - [OS Therapies prices up to $10 million senior secured convertible note private placement](https://longbridge.com/en/news/295708936.md) - [Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results](https://longbridge.com/en/news/295310504.md) - [Metabolic disorders biotech Vogenx prices IPO at $13, the high end of the range](https://longbridge.com/en/news/295671099.md)